Altamira Therapeutics (CYTO)
NASDAQ:CYTO
US Market
Holding CYTO?
Track your performance easily

Altamira Therapeutics (CYTO) Financial Statements

597 Followers

Altamira Therapeutics Financial Overview

Altamira Therapeutics's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Altamira Therapeutics is scheduled to report earnings on April 9, 2025, and the estimated EPS forecast is $-0.58. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Jun 22Dec 21Jun 21
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsCHF 617.41KCHF 15.39KCHF 372.65KCHF 984.19KCHF 8.47M
Total AssetsCHF 7.69MCHF 6.30MCHF 18.48MCHF 18.84MCHF 23.73M
Total DebtCHF 0.00CHF 6.21MCHF 5.22MCHF 575.74KCHF 0.00
Net DebtCHF -617.41KCHF 6.20MCHF 4.85MCHF -408.45KCHF -8.47M
Total LiabilitiesCHF 1.24MCHF 15.11MCHF 10.80MCHF 6.13MCHF 3.65M
Stockholders EquityCHF 6.46MCHF -8.81MCHF 7.68MCHF 12.70MCHF 20.09M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in CHF

Altamira Therapeutics Earnings and Revenue History

Altamira Therapeutics Debt to Assets

Altamira Therapeutics Cash Flow

Altamira Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis